Goldman Sachs Group Inc Neurocrine Biosciences Inc Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
A detailed history of Goldman Sachs Group Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 983,799 shares of NBIX stock, worth $109 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
983,799
Previous 1,017,154
3.28%
Holding current value
$109 Million
Previous $117 Million
14.67%
% of portfolio
0.02%
Previous 0.02%
Shares
20 transactions
Others Institutions Holding NBIX
# of Institutions
655Shares Held
95.2MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.57 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.12 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$541 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$334 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$281 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.6B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...